CCND1 and melanoma: It has been reported that in a subset of melanomas (<8%), the CCND1 gene is amplified, leading to an overproduction of cyclin D1, which enables an aberrant proliferation, diminishing the effectiveness of treatment, and generating a therapy resistance mechanism [32].